BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 2947818)

  • 41. Effect of short-term cyclic administration of cyproterone acetate on pituitary-ovarian function in the human.
    Kumari GI; Das RP; Madoiya KK; Jain AK; Roy S
    Fertil Steril; 1977 Nov; 28(11):1168-74. PubMed ID: 562781
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
    Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pulsatile luteinizing hormone patterns in long term oral contraceptive users.
    Hemrika DJ; Slaats EH; Kennedy JC; de Vries Robles-Korsen TJ; Schoemaker J
    J Clin Endocrinol Metab; 1993 Aug; 77(2):420-6. PubMed ID: 8345046
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Effect of the steroid sex hormones on the LH and FSH responses to LHRH in the normal subject].
    Lemarchand-Béraud T; Reymond M; Rappoport G; Magrini G; Gomez J
    Pathol Biol (Paris); 1975 Dec; 23(10):917-22. PubMed ID: 772543
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel peptides in ovarian follicular fluid: implications for contraceptive development.
    Schwartz NB
    Res Front Fertil Regul; 1982 Sep; 2(2):1-11. PubMed ID: 12179632
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
    Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
    Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
    Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
    Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current status of antagonistic analogs of LH-RH as a contraceptive method in the female.
    Schally AV
    Res Front Fertil Regul; 1983 Jul; 2(5):1-16. PubMed ID: 12179624
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Suppression in the secretion of follicle-stimulating hormone and luteinizing hormone, and ovarian follicle development in heifers continuously infused with a gonadotropin-releasing hormone agonist.
    Gong JG; Campbell BK; Bramley TA; Gutierrez CG; Peters AR; Webb R
    Biol Reprod; 1996 Jul; 55(1):68-74. PubMed ID: 8793060
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effects of estrogen and progesterone on the functional capacity of the gonadotrophs.
    Lasley BL; Wang CF; Yen SS
    J Clin Endocrinol Metab; 1975 Nov; 41(5):820-6. PubMed ID: 1102551
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles.
    Pakarinen PI; Suvisaari J; Luukkainen T; Lähteenmäki P
    Fertil Steril; 1997 Jul; 68(1):59-64. PubMed ID: 9207585
    [TBL] [Abstract][Full Text] [Related]  

  • 52. GnRH analogues for contraception.
    Fraser HM
    Br Med Bull; 1993 Jan; 49(1):62-72. PubMed ID: 8324616
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Contraception with cyclic administration of buserelin and gestagens: increase in testosterone and free testosterone serum concentration].
    Pietzsch V; Kuhl H
    Geburtshilfe Frauenheilkd; 1991 Oct; 51(10):819-23. PubMed ID: 1837002
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Ultrasonic and hormonal monitoring of the ovaries during mini-dose oral contraception].
    Doyen J; Schaaps JP; Lambotte R
    Contracept Fertil Sex (Paris); 1987 May; 15(5):529-33. PubMed ID: 12268693
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chronic treatment with the gonadotropin-releasing hormone agonist D-Ser(TBU)6-EA10-LRH for contraception in women and men.
    Nillius SJ; Bergquist C; Wide L
    Int J Fertil; 1980; 25(3):239-46. PubMed ID: 6108935
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pituitary and ovarian response to acute stimulation with LH-RH in normal and anovulatory women.
    Aparicio NJ; Casas PR; Galimberti DM; de Laborde NP; Badano A; García EP; Meichi HR; Mirkin A; Szejner M; Jaitt A; Margulies M; Rosner JM
    Int J Fertil; 1977; 22(1):6-15. PubMed ID: 18416
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Timing of onset of contraceptive effectiveness in Depo-Provera users. II. Effects on ovarian function.
    Petta CA; Faúndes A; Dunson TR; Ramos M; DeLucio M; Faúndes D; Bahamondes L
    Fertil Steril; 1998 Nov; 70(5):817-20. PubMed ID: 9806559
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gonadotroph and corpus luteum responses to two successive intranasal doses of a luteinizing hormone-releasing hormone agonist at different days after the midcycle luteinizing hormone surge.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Fertil Steril; 1983 May; 39(5):661-7. PubMed ID: 6404660
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ovarian morphology and pituitary gonadotrophins in serum during and after long-term treatment with oral contraceptives.
    Starup J; Visfeldt J
    Acta Obstet Gynecol Scand; 1974; 53(2):161-7. PubMed ID: 4822347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.